AMENDMENTS TO THE CLAIMS

1. **(Currently amended)** An isolated polypeptide having at least 80% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~;

(b) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~, lacking ~~its associated signal peptide~~ amino acids 1-33; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56), lacking its associated signal peptide; or~~

~~(e)~~ (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203005;

wherein said isolated polypeptide is more highly expressed in melanoma compared to normal skin or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in melanoma compared to normal skin .

2. **(Currently amended)** The isolated polypeptide of Claim 1 having at least 85% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~;

(b) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~, lacking ~~its associated signal peptide~~ amino acids 1-33; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56), lacking its associated signal peptide; or~~

~~(e)~~ (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203005;

wherein said isolated polypeptide is more highly expressed in melanoma compared to normal skin or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in melanoma compared to normal skin .

3. **(Currently amended)** The isolated polypeptide of Claim 1 having at least 90% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~;

(b) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~, lacking ~~its associated signal peptide~~ amino acids 1-33; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56), lacking its associated signal peptide; or~~

~~(e)~~ (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203005;

wherein said isolated polypeptide is more highly expressed in melanoma compared to normal skin or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in melanoma compared to normal skin.

4. **(Currently amended)** The isolated polypeptide of Claim 1 having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~;

(b) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~, lacking ~~its associated signal peptide~~ amino acids 1-33; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56), lacking its associated signal peptide; or~~

~~(e)~~ (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203005;

wherein said isolated polypeptide is more highly expressed in melanoma compared to normal skin or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in melanoma compared to normal skin.

5. **(Currently amended)** The isolated polypeptide of Claim 1 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~;

(b) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~, lacking ~~its associated signal peptide~~ amino acids 1-33; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56), lacking its associated signal peptide; or~~

~~(e)~~ (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203005;

wherein said isolated polypeptide is more highly expressed in melanoma compared to normal skin or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in melanoma compared to normal skin.

6. **(Currently amended)** An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~;

(b) the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~, lacking ~~its associated signal peptide~~ amino acids 1-33; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 56 (SEQ ID NO:56), lacking its associated signal peptide; or~~

~~(e)~~ (c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203005.

7. **(Currently amended)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~.

8. **(Currently amended)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of ~~shown in Figure 56 (~~SEQ ID NO:56~~)~~, lacking ~~its associated signal peptide~~ amino acids 1-33.

9. **Canceled**

10. **Canceled**

11. **(Original)** The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203005.

12. **(Original)** A chimeric polypeptide comprising a polypeptide according to Claim 1 fused to a heterologous polypeptide.

13. **(Original)** The chimeric polypeptide of Claim 12, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

DELETION OF INVENTORS

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe.